Literature DB >> 28273630

Occurrence and co-occurrence of hallucinations by modality in schizophrenia-spectrum disorders.

Simon McCarthy-Jones1, David Smailes2, Aiden Corvin1, Michael Gill1, Derek W Morris3, Timothy G Dinan4, Kieran C Murphy5, F Anthony O Neill6, John L Waddington7, Gary Donohoe3, Robert Dudley8.   

Abstract

It is not only unclear why hallucinations in schizophrenia occur with different prevalence by modality, but also to what extent they do. Reliable prevalence estimates of hallucinations by modality in schizophrenia are currently lacking, particularly for non-auditory hallucinations. Studies have also tended to report lifetime, not point prevalence by modality. This study assessed the prevalence and co-occurrence of hallucinations, for both lifetime and point prevalence, across the auditory, visual, olfactory, and tactile modalities, in people diagnosed with chronic schizophrenia-spectrum disorders in Ireland (N=693) and Australia (N=218). Lifetime prevalence was 64-80% auditory, 23-31% visual, 9-19% tactile, and 6-10% olfactory. Past month prevalence was 23-27% auditory, 5-8% visual, 4-7% tactile, and 2% olfactory. The majority of participants had only hallucinated in one modality, with this nearly always being the auditory. Approximately one-third had hallucinated in two modalities, most commonly the auditory and visual. Most currently hallucinating patients also hallucinated in a single modality, again, nearly always the auditory. Whereas 30-37% of patients with lifetime auditory hallucinations had experienced visual hallucinations, 83-97% of patients with experience of visual hallucinations had experienced auditory hallucinations. These findings help delineate the modality distribution of hallucinations in schizophrenia, and provide an explanatory target for theoretical models.
Copyright © 2017 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Auditory; Olfactory; Psychosis; Tactile; Visual

Mesh:

Year:  2017        PMID: 28273630     DOI: 10.1016/j.psychres.2017.01.102

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  23 in total

1.  Successful treatment of intractable visual hallucinations with 5-HT 2A antagonist ketanserin.

Authors:  Iris E C Sommer; Hidde Kleijer; Lucy Visser; Teus van Laar
Journal:  BMJ Case Rep       Date:  2018-06-27

2.  Main Symptomatic Treatment Targets in Suspected and Early Psychosis: New Insights From Network Analysis.

Authors:  Natalia Jimeno; Javier Gomez-Pilar; Jesus Poza; Roberto Hornero; Kai Vogeley; Eva Meisenzahl; Theresa Haidl; Marlene Rosen; Joachim Klosterkötter; Frauke Schultze-Lutter
Journal:  Schizophr Bull       Date:  2020-07-08       Impact factor: 9.306

3.  Visual hallucinations associated with multimodal hallucinations, suicide attempts and morbidity of illness in psychotic disorders.

Authors:  Virginie-Anne Chouinard; Ann K Shinn; Linda Valeri; Philippe A Chouinard; Margaret E Gardner; A Esin Asan; Bruce M Cohen; Dost Öngür
Journal:  Schizophr Res       Date:  2019-03-03       Impact factor: 4.939

4.  Brain-based ranking of cognitive domains to predict schizophrenia.

Authors:  Teresa M Karrer; Danielle S Bassett; Birgit Derntl; Oliver Gruber; André Aleman; Renaud Jardri; Angela R Laird; Peter T Fox; Simon B Eickhoff; Olivier Grisel; Gaël Varoquaux; Bertrand Thirion; Danilo Bzdok
Journal:  Hum Brain Mapp       Date:  2019-07-16       Impact factor: 5.038

5.  Negative voice-content as a full mediator of a relation between childhood adversity and distress ensuing from hearing voices.

Authors:  Cherise Rosen; Simon McCarthy-Jones; Nev Jones; Kayla A Chase; Rajiv P Sharma
Journal:  Schizophr Res       Date:  2018-03-23       Impact factor: 4.939

6. 

Authors:  Clément Dondé; Frédéric Haesebaert; Emmanuel Poulet; Marine Mondino; Jérôme Brunelin
Journal:  Can J Psychiatry       Date:  2019-12-13       Impact factor: 4.356

7.  Prediction of activation patterns preceding hallucinations in patients with schizophrenia using machine learning with structured sparsity.

Authors:  Amicie de Pierrefeu; Thomas Fovet; Fouad Hadj-Selem; Tommy Löfstedt; Philippe Ciuciu; Stephanie Lefebvre; Pierre Thomas; Renaud Lopes; Renaud Jardri; Edouard Duchesnay
Journal:  Hum Brain Mapp       Date:  2018-01-16       Impact factor: 5.038

8.  The Strasbourg Visual Scale: A Novel Method to Assess Visual Hallucinations.

Authors:  Anne Giersch; Thomas Huard; Sohee Park; Cherise Rosen
Journal:  Front Psychiatry       Date:  2021-06-09       Impact factor: 4.157

9.  Differential Effectiveness of Atypical Antipsychotics on Hallucinations: A Pragmatic Randomized Controlled Trial.

Authors:  Igne Sinkeviciute; Kenneth Hugdahl; Christoffer Bartz-Johannessen; Rune Andreas Kroken; Else-Marie Løberg; Eirik Kjelby; Maria Anna Rettenbacher; Inge Joa; Solveig Klæbo Reitan; Renata Alisauskiene; Farivar Fathian; Erik Johnsen
Journal:  J Clin Psychopharmacol       Date:  2021 Jul-Aug 01       Impact factor: 3.153

10.  Advancing clinical response characterization to frontotemporal transcranial direct current stimulation with electric field distribution in patients with schizophrenia and auditory hallucinations: a pilot study.

Authors:  Marine Mondino; Clara Fonteneau; Louis Simon; Clément Dondé; Frédéric Haesebaert; Emmanuel Poulet; Jerome Brunelin
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2020-06-12       Impact factor: 5.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.